• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: encorafenib + binimetinib
Trade Name:
Date Designated: 11/19/2013
Orphan Designation: Treatment of Stage IIB-IV melanoma positive for the BRAF mutation.
Orphan Designation Status: Designated/Approved
Array BioPharma, Inc.
100 Cambridgepark Drive
Suite 505
Cambridge, Massachusetts 02140
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: encorafenib + binimetinib
Trade Name:
Marketing Approval Date: 06/27/2018
Approved Labeled Indication: MEKTOVI® is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test
Exclusivity End Date: 06/27/2025 
Exclusivity Protected Indication* :  BRAFTOVI¿ (encorafenib) and MEKTOVI® (binimetinib) indicated, in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
2 Generic Name: encorafenib + binimetinib
Trade Name:
Marketing Approval Date: 06/27/2018
Approved Labeled Indication: BRAFTOVI¿ is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test
Exclusivity End Date: 06/27/2025 
Exclusivity Protected Indication* :  BRAFTOVI¿ (encorafenib) and MEKTOVI® (binimetinib) indicated, in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.
-
-